Drug treatment of primary hyperparathyroidism: use of clodronate disodium.

Clodronate disodium (dichloromethylene diphosphonate), a specific inhibitor of bone resorption, was given by mouth (1.0-3.2 g daily) to nine patients with primary hyperparathyroidism for two to 32 weeks so that its clinical and metabolic effects could be evaluated. Bone resorption decreased in all p...

Full description

Saved in:
Bibliographic Details
Main Authors: Douglas, D L, Kanis, J A, Paterson, A D, Beard, D J, Cameron, E C, Watson, M E, Woodhead, S, Williams, J, Russell, R G
Format: Artigo
Language:Inglês
Published: 1983
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC1546876/
https://ncbi.nlm.nih.gov/pubmed/6218861
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items